Drug profile · INN
nemolizumab-ilto
NEMLUVIO
nemolizumab-ilto (NEMLUVIO) is a interleukin-31 receptor subunit alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — nemolizumab-ilto
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
nemolizumab-ilto (NEMLUVIO) is a interleukin-31 receptor subunit alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-31 receptor subunit alpha inhibitor
Primary target: Interleukin-31 receptor subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is nemolizumab-ilto?
nemolizumab-ilto (NEMLUVIO) is a interleukin-31 receptor subunit alpha inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for nemolizumab-ilto?
NEMLUVIO is a marketed brand name for nemolizumab-ilto. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nemolizumab-ilto?
nemolizumab-ilto has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.